Stock & Company Details
Agenus Inc $AGEN
Price:
46,691,331
42M
$207M
52 Week High:
$66.15
10 Day Average Volume:
42,760,466
-0.57
50 Day Moving Average:
$156.49
52 Week Low:
$43.74
30 Day Average Volume:
49,506,373
$4.94
2021-02-05
0.95
30 Day Change:
13%
3 Month Change:
-0.32%
Health Technology
AGEN technical indicators
Latest Agenus Inc (AGEN) technical indicators as of 2026-07-21: RSI, MACD, moving averages (SMA & EMA), Bollinger Bands, Stochastic, ADX, ATR, CCI, OBV and ROC.
RSI 14:
69.49 8.1%
MACD:
0.53 11.5%
SMA 50:
$3.54 1.0%
SMA 200:
$3.68 0.2%
EMA 20:
$4.25 3.4%
Bollinger Bands:
5.96 / 1.90
Stochastic:
38.24 7.6%
ADX 14:
37.32 8.7%
ATR 14:
0.64 3.6%
CCI 20:
103.73 9.2%
OBV:
161.44M 1.6%
ROC 12:
59.89% 30.9%
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Finance Bot
Ask your questions
Start by typing a question below.
